Bristol-Myers Squibb and Starboard Value square off over Celgene deal
Less than one month before shareholders vote on the deal, Bristol-Myers Squibb Co.'s proposed $74 billion acquisition of Celgene Corp. is coming under intense fire from an activist investor.
Earlier this year, New York City-based Bristol-Myers Squibb (NYSE: BMY) said its acquisition of Summit, New Jersey-based Celgene (Nasdaq: CELG) would strengthen its cancer and inflammatory disease drug products.
But activist investor Starboard Value said "we believe the proposed acquisition of Ce lgene is ill-advised…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ben Miller Source Type: news
More News: Cancer | Cancer & Oncology | Health Management | Mergers and Aquisitions | Pharmaceuticals